Inhibition of TOMM34‐ATP5B interaction by Gboxin weakened mitochondrial OXPHOS and abrogated metformin adaptation, indicating the potential clinical value of the combinational use of Gboxin and metformin in the treatment of liver cancer. The gene discussed is TOMM34; the disease is liver cancer.